We are live on ! Find out more
HC

Hampstead Capital Portfolio holdings

AUM $55.8M
1-Year Est. Return 2.76%
This Fund
S&P 500
This Quarter Est. Return
+3.11%
1 Year Est. Return
+2.76%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
-$663K
Cap. Flow
-$3.13M
Cap. Flow %
-3.1%
Top 10 Hldgs %
45.49%
Holding
34
New
2
Increased
10
Reduced
10
Closed
2

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$3.18M
2
AIG icon
American International
AIG
+$1.62M
3
PXD
Pioneer Natural Resource Co.
PXD
+$1.44M
4
INVX
Innovex International
INVX
+$870K
5
EXC icon
Exelon
EXC
+$750K

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$3.65M
2
PFE icon
Pfizer
PFE
+$3.12M
3
GM icon
General Motors
GM
+$1.21M
4
MOS icon
The Mosaic Company
MOS
+$1.08M
5
DXC icon
DXC Technology
DXC
+$725K

Sector Composition

Rank Sector Weight
1 Healthcare 19.28%
2 Communication Services 15.82%
3 Energy 15.73%
4 Utilities 11.49%
5 Technology 9.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
T icon
1
AT&T
T
$159B
$8.19M 8.11%
276,716
-794
-0.3% -$22.5K
GILD icon
2
Gilead Sciences
GILD
$162B
$4.94M 4.9%
61,000
– –
EXC icon
3
Exelon
EXC
$47.2B
$4.71M 4.66%
175,250
+28,040
+19% +$750K
PXD
4
DELISTED
Pioneer Natural Resource Co.
PXD
$4.43M 4.38%
30,000
+10,000
+50% +$1.44M
CELG
5
DELISTED
Celgene Corp
CELG
$4.38M 4.33%
30,000
-5,000
-14% -$681K
TMUS icon
6
T-Mobile US
TMUS
$185B
$4.32M 4.28%
70,000
– –
AIG icon
7
American International
AIG
$41.7B
$4.05M 4.01%
66,000
+26,000
+65% +$1.62M
MSFT icon
8
Microsoft
MSFT
$3.45T
$3.73M 3.69%
50,000
– –
AAPL icon
9
Apple
AAPL
$4.54T
$3.7M 3.66%
96,000
– –
RY icon
10
Royal Bank of Canada
RY
$291B
$3.5M 3.46%
45,200
-1,800
-4% -$134K
XOM icon
11
ExxonMobil
XOM
$644B
$3.49M 3.46%
42,600
+1,000
+2% +$79.4K
PFE icon
12
Pfizer
PFE
$143B
$3.49M 3.46%
103,081
-97,179
-49% -$3.12M
SO icon
13
Southern Company
SO
$109B
$3.48M 3.45%
70,900
+2,500
+4% +$121K
VZ icon
14
Verizon
VZ
$195B
$3.47M 3.44%
70,100
-5,200
-7% -$245K
KO icon
15
Coca-Cola
KO
$377B
$3.47M 3.43%
77,000
+2,000
+3% +$91K
VTRS icon
16
Viatris
VTRS
$20.4B
$3.45M 3.42%
110,000
-20,000
-15% -$679K
CVX icon
17
Chevron
CVX
$392B
$3.44M 3.41%
29,300
-3,200
-10% -$349K
PM icon
18
Philip Morris
PM
$297B
$3.43M 3.4%
30,900
+2,300
+8% +$268K
PPL
19
PPL Corp
PPL
$26.5B
$3.4M 3.37%
89,700
+3,100
+4% +$120K
WLK icon
20
Westlake Corp
WLK
$9.03B
$3.32M 3.29%
40,000
– –
MRK icon
21
Merck
MRK
$322B
$3.2M 3.17%
+52,400
New +$3.18M
FLR icon
22
Fluor
FLR
$7.01B
$2.61M 2.59%
62,000
+15,000
+32% +$622K
GM icon
23
General Motors
GM
$80.4B
$2.5M 2.48%
62,000
-33,000
-35% -$1.21M
HPE icon
24
Hewlett Packard
HPE
$63.4B
$2.35M 2.33%
160,000
+18,210
+13% +$248K
RRC icon
25
Range Resources
RRC
$9.38B
$2.35M 2.33%
120,000
– –
1
2

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
EIC
ENA Investment Capital London, United Kingdom $61.8M AUM
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
BOIA
Bush ODonnell Investment Advisors St Louis, Missouri $65.2M AUM 13.39% 1-Year Est. Return

Hampstead Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Hampstead Capital held 34 positions worth $101M, down 0.65% from $102M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Hampstead Capital withdrew a net $3.13M in Q3 2017, closing 2 positions and reducing 10 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $3.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 24% a quarter earlier, followed by Communication Services and Energy.

Against the trend, Hampstead Capital opened a new position in Merck worth $3.2M.

  • Hampstead Capital's largest Q3 2017 buy was Merck: 52,400 shares worth $3.2M.
  • Hampstead Capital added most to American International in Q3 2017, an estimated $1.62M increase.
  • Hampstead Capital's biggest Q3 2017 reduction was Pfizer, cutting an estimated $3.12M.
  • Hampstead Capital fully exited Teva Pharmaceuticals in Q3 2017, selling an estimated $3.65M.
  • Hampstead Capital's ten largest holdings make up 45% of its $101M portfolio in Q3 2017.
  • Hampstead Capital opened 2 new positions and closed 2 in Q3 2017.
  • Hampstead Capital's portfolio value fell 0.65% quarter-over-quarter to $101M.

Based on Hampstead Capital's 13F filing for Q3 2017, filed 15 Nov 2017.